Novartis - Afrikan Heroes

Novartis Reaches Milestone, Delivers 1 Billion Courses of Antimalaria Treatment

May 18, 2021

Dr. Lutz Hegemann, Group Head, Corporate Affairs and Global Health, Novartis

Global pharmaceutical giant Novartis has delivered 1 billion courses of antimalarial treatment, including 430 million pediatric treatments, largely at no profit since 1999; With other innovations, the Novartis artemisinin-based combination therapy (ACT) contributed to reduce malaria deaths by nearly half over the same timeframe; Novartis continues to invest in research and development for next-generation antimalarials to combat the threat of artemisinin resistance.

Novartis announced today that it has delivered one billion courses of antimalarial treatment since 1999. More than 90% of this artemisinin-based combination therapy (ACT) was supplied without profit to malaria-endemic countries around the globe.

ACTs are the standard of care for the treatment of P. falciparum malaria, the most deadly form of the disease, responsible for over 99% of cases in Africa and half of cases in Asia [2]. Since the turn of the century, ACTs have transformed malaria treatment and contributed to the dramatic reduction in malaria deaths.

Working with Chinese partners, Novartis launched the first fixed-dose ACT (artemether-lumefantrine) in 1999. Artemisinin is a natural compound found in the plant Artemisia annua, or sweet wormwood, and has shown to clear malaria parasites in the blood. ACTs combine an artemisinin derivative with a partner drug to reduce the risk of resistance if artemisinin is given alone.

Adoption of ACTs as first-line treatment by the World Health Organization (WHO) has been critical to the global malaria response. Since 2000, the WHO estimates that 1.5 billion malaria cases have been averted and 7.6 million lives saved.1 Along with malaria prevention tools and better diagnostics, ACTs remain a key component of the global drive to reach malaria elimination.

In 2001, two years after the launch of its ACT, Novartis signed an agreement with the WHO, committing to make the antimalarial available without profit to the public sector of malaria-endemic countries. Although the agreement expired in 2011, Novartis continues to provide treatments on the same terms as before.

“This is a landmark moment in the fight against malaria. Over the last 20 years, Novartis has delivered one billion treatments in more than 70 countries,” said Dr. Lutz Hegemann, Group Head, Corporate Affairs and Global Health, Novartis. “We could not have achieved this milestone without the support of our global partners and those we work with on the ground in endemic countries.”

Children bear a significant burden of malaria disease and death. This led Novartis and Medicines for Malaria Venture (MMV) to partner on the development of the first dispersible ACT formulated specifically for children. Of the 1 billion treatments delivered, more than 430 million are the pediatric formulation launched in 2009. This pediatric treatment has contributed to a significant reduction in malaria deaths in children: in 2010, a child died every 30 seconds from malaria and now it is estimated that a child dies every two minutes. Although this is a massive improvement, there is still a long way to go.

Novartis continues to spearhead the use of ACTs to treat malaria. The company is now testing a new ACT formulation for infants weighing less than five kilograms in collaboration with the PAMAfrica research consortium led by MMV. This is one of the most vulnerable groups affected by malaria, for whom there is currently no approved treatment.

Over the last few years, worrying signs have been observed of emerging drug resistance to ACTs in South East Asia, and more recently in Africa. If widespread resistance to ACTs occurs, particularly in Africa, new effective treatments will be urgently needed. In 2018, Novartis committed to invest more than USD 100 million over five years to further advance research and development of next-generation treatments.

Novartis currently leads five malaria development programs worldwide, featuring three compounds that employ new mechanisms of action and activity against artemisinin-resistant strains of the disease.

KAF156 (ganaplacide) belongs to a novel class of antimalarial compounds that act against both the blood and liver stages of the parasite’s lifecycle. It demonstrated activity against both P. vivax and P. falciparum malaria, including artemisinin-resistant parasites. Novartis leads the development of this compound with scientific and financial support from MMV and from EDCTP via the WANECAM2 Consortium.

KAE609 (cipargamin) is another novel antimalarial compound demonstrating rapid clearance of parasites pre-clinically and in patients. Novartis is leading the development of KAE609 with financial support from the Wellcome Trust and in collaboration with the PAMAFRICA Consortium supported by EDCTP and led by MMV.

In 2020, the company discovered another novel malaria compound, INE963, which has an entirely new mechanism of action which will begin clinical trials in 2021. INE963 is a fast-acting, long-lasting antimalarial that holds promise for a high barrier to resistance. It was discovered with support from MMV and received the organization’s “Project of the Year” award in 2020.

Kelechi Deca

Kelechi Deca has over two decades of media experience, he has traveled to over 77 countries reporting on multilateral development institutions, international business, trade, travels, culture, and diplomacy. He is also a petrol head with in-depth knowledge of automobiles and the auto industry

Novartis Launches Medicines for Symptomatic Treatment of COVID-19

July 20, 2020

Dr Lutz Hegemann, Chief Operating Officer for Global Health at Novartis

Global pharmaceutical giant Novartis has launched a first-of-its-kind not-for-profit portfolio of medicines to be sold at zero-profit to governments in up to 791 eligible countries during the pandemic and until a vaccine or curative treatment is available. The Portfolio of 15 generic and over-the-counter (OTC) medicines from Sandoz division will address urgent unmet needs of low- and lower-middle-income countries to treat patients with COVID-19 symptoms; Portfolio will be sold at zero-profit to governments in up to 791 eligible countries during the pandemic and until a vaccine or curative treatment is available; Early access to treatment for managing COVID-19 symptoms is critical to preventing healthcare system overload.

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms of COVID-19 – a critical need in the absence of a vaccine or curative treatment. Inflammation and respiratory problems linked to COVID-19 can cause severe medical complications and can lead to death in some people, putting immense strain on fragile healthcare systems.

The Novartis COVID-19 portfolio includes 15 medicines from its Sandoz division for gastro-intestinal illness, acute respiratory symptoms, pneumonia as well as septic shock. The medicines were chosen based on clinical relevance and availability to ensure demand can be met globally. The medicines will be made available to governments, Non-Governmental Organizations (NGOs) and other institutional customers in up to 79 eligible countries at zero-profit to support financially-strained healthcare systems. Countries will have the flexibility to select the medicines in the portfolio that meet their healthcare needs. Eligible countries must be included on the World Bank’s list of LICs & LMICs1.

“Access to medicine can be a challenge for patients in low- and lower-middle-income countries and the situation has worsened during COVID-19. With our COVID-19 portfolio, we wish to help address the additional healthcare demands of the pandemic in the countries we are targeting,” said Dr Lutz Hegemann, Chief Operating Officer for Global Health at Novartis.

“This initiative builds on our earlier global commitment to keep prices stable for a basket of essential drugs used to treat COVID-19 patients,” says Sandoz CEO Richard Saynor. “The COVID-19 Response Portfolio for low-income and lower-middle-income countries is designed to support governments in treating COVID-19 symptoms before they lead to complications in patients.”

The following medicines are included in the Novartis COVID-19 Response Portfolio are Amoxicillin, Ceftriaxone, Clarithromycin, Colchicine, Dexamethasone, Dobutamine, Fluconazole, Heparin, Levofloxacin, Loperamide, Pantoprazole, Prednisone, Prednisolone, Salbutamol, Vancomycin. The portfolio will be offered in addition to the Novartis Access portfolio (on- and off-patent medicines against key non-communicable diseases) via the local Novartis or Sandoz affiliate.

This global pandemic has placed extreme pressure on healthcare systems in low- and lower-income countries. The pandemic response portfolio complements the previously launched Novartis COVID-19 Response Fund to support healthcare workers and communities in over 50 projects around the world.

The COVID-19 medicines portfolio is Novartis latest contribution to the global effort to combat the pandemic and support the stability of global healthcare systems. The company has committed to donating USD 40 million to support communities around the world impacted by the pandemic. In addition, Novartis has been active in two key cross-industry research initiatives, the COVID-19 Therapeutics Accelerator, coordinated by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard, as well as a COVID-19 directed partnership organized by the Innovative Medicines Initiative (IMI). Novartis continues to provide hydroxychloroquine for ongoing investigator-initiated trials (IITs) and upon government requests, as appropriate.

The company is also separately supporting COVID-19 related clinical investigations of several Novartis medicines. To support access, the Novartis generics and biosimilars division Sandoz became the first company to commit to keeping stable prices for a basket of essential medicines that may help in the treatment of COVID-19 and entered into a partnership with US-based Civica Rx to support stable supply of essential generic hospital medicines. Furthermore, AveXis, Novartis gene therapy unit, entered into a manufacturing agreement with Massachusetts Eye and Ear and Massachusetts General Hospital to produce its novel genetic COVID-19 vaccine candidate called AAVCOVID.

Kelechi Deca

Kelechi Deca has over two decades of media experience, he has traveled to over 77 countries reporting on multilateral development institutions, international business, trade, travels, culture, and diplomacy. He is also a petrol head with in-depth knowledge of automobiles and the auto industry

Public-Private Collaboration to Accelerate Access to Health Services for about 2 Million People in Africa

January 17, 2020

The world’s leading pharmaceutical and personal healthcare manufacturing Giants such as Johnson & Johnson , Lilly, Novartis , Pfizer , GSK and the Bill & Melinda Gates Foundation have joined forces with Philanthropic organisations like the Last Mile Health and Living Goods to increase access to community-based primary healthcare for nearly 1.7 million people in up to six African countries.

This laudable initiative is part of their shared commitment to accelerate universal health coverage. The Health Worker Training Initiative is a three-year investment, generously matched by The Audacious Project, and totals USD $18 million.

Harnessing the synergy of cross-industry collaboration is key to advancing universal health coverage. Living Goods and Last Mile Health have pioneered the community health worker model and are continually exploring novel approaches to training and retaining community health workers. By teaming up with Johnson & Johnson, Lilly, Novartis, Pfizer, GSK and the Bill & Melinda Gates Foundation, precious resources and acumen can be maximized. All are united by the belief that community health workers play a catalytic role, and all share a commitment towards advancing universal health coverage.

Leveraging the unique expertise of each organization will drive tech innovation and deepen impact. In addition to financial contributions, industry partners will contribute disease-specific expertise and experience in the discovery and development of new tools, which will supplement the community health worker models pioneered by Last Mile Health and Living Goods, in partnership with government.

Investing in community health workers produces some of the best returns in health. Community health workers can yield a 10:1 return on investment, due to a healthier population, increased employment, and lower odds of health crises. In addition, community health workers can help primary healthcare systems serve the majority of a population’s health needs, which means community health workers are one of the most efficient and effective ways to achieve universal health coverage. This partnership is a response to the growing call to action globally to advance universal health coverage and Sustainable Development Goal 3.

“Focused investment in community health workers can accelerate progress to make universal health coverage a reality,” said Dave Ricks, chairman and CEO of Lilly and president of the International Federation of Pharmaceutical Manufacturers & Associations. “Public-private collaboration is critical to help governments lower barriers to quality care and innovative medicines that save and improve people’s lives.”

“Community health workers are the critical frontline to sustainably impact the health of communities in resource poor settings,” said Vas Narasimhan, CEO of Novartis. “Novartis is committed to strengthening healthcare systems and is proud to be part of this coalition to use digital technologies to reimagine the future of community health delivery.”

The three-year investment will cover three areas mainly; supporting the training and deployment of 2,500 digitally-enabled community health workers, reaching nearly 1.7 million people by 2022. Community health workers will be trained and deployed in Liberia, Kenya, Uganda, Malawi and up to two additional countries.S

Supporting Last Mile Health’s Community Health Academy, which is an open source, digital learning platform for community health workers and health systems leaders used worldwide. Training curricula for community health workers initially focuses on diarrheal diseases, family planning, malaria and pneumonia, with further modules expected to address non-communicable diseases, such as diabetes and hypertension.

And the last would be to contribute expertise and personnel to Living Goods’ new Kenya Performance Lab to develop mobile-based tech innovations that will improve community health worker productivity, strengthen supply chains and better identify obstacles to coverage.

The Lab will leverage the knowledge and assets of partners in areas including data science, behavior change, performance management, analytics and technical health expertise. Innovations would be introduced in Kenya and then scaled to other countries within the broader initiative.

Together, these pieces of the investment aim to scale up access to life-saving primary healthcare while building stronger, tech-enabled community health programs for the future.

“Well-trained community health workers play an integral role in providing quality care in low-resource settings,” said Andrin Oswald, Co-chair of the CEO Roundtable Executive Council and Director of Life Sciences Partnerships at the Bill & Melinda Gates Foundation. “The Gates Foundation is committed to working with partners across sectors to achieve universal health coverage, which is necessary to achieving the Sustainable Development Goals and reducing the burden of diseases that disproportionately affect pregnant women and young children. We thank the companies involved in this initiative for their efforts to increase data-driven solutions to train and deploy effective community health workers.”

“This partnership will play a critical role in helping to scale and empower the world’s most promising health resource—community health workers—so that they can thrive and effectively save lives,” said Dr. Jane Aceng, Uganda’s Minister of Health. “Ensuring community health workers have the right training, digital technology, medical equipment and supervision is critical for ensuring they can help transform health outcomes, no matter where people live.”

Each of the six investors will contribute USD $1.5 million total over the next three years. This funding will be matched by the Audacious Project through an existing USD $50 million matching commitment to scale community health workers in Africa, resulting in an USD $18 million total investment.

This investment will also support the sustainability of community health worker programs. Living Goods and Last Mile Health partner with governments to deploy digitally-empowered community health workers. Not only will this partnership support community health workers to reach more patients, but the curricula and tools developed through the investment will support improved community health worker performance for years to come.

“We are inspired that healthcare companies are taking collective action to strengthen community health systems in the public sector across sub-Saharan Africa to advance universal health coverage,” said Liz Jarman, CEO of Living Goods, and Dr. Raj Panjabi, CEO of Last Mile Health.

“This partnership is much more than a financial commitment; it joins a growing movement of philanthropists, companies, and governments that have committed to scale digitally-empowered community health workers and build stronger primary healthcare systems across Africa to ultimately save more lives”, he added.

Kelechi Deca

Kelechi Deca has over two decades of media experience, he has traveled to over 77 countries reporting on multilateral development institutions, international business, trade, travels, culture, and diplomacy. He is also a petrol head with in-depth knowledge of automobiles and the auto industry